This document represents an update of the British Society of Haematology Guideline published in 2014 due to advances in understanding the biology and therapy of the myelodysplastic syndromes (MDS).1 The objective of these guidelines is to provide healthcare professionals with clear guidance on the management of adult patients with MDS. Individual circumstances may dictate an alternative approach. A separate British Society for Haematology (BSH) guideline covers the Diagnosis and Evaluation of Prognosis of Adult MDS which is published alongside this Guideline. A separate good-practice paper detailing the management of patients with chronic myelomonocytic leukaemia (CMML) will follow and is not considered in these Guidelines.

Dr Sally Killick Audio Commentary - Length: 17:39

Declaration of Interests

The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.